FDA approves obinutuzumab to reduce relapse risk in childhood-onset idiopathic nephrotic ...

The FDA approved obinutuzumab for patients aged 2 and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome (INS), showing superior sustained remission rates versus mycophenolate mofetil in the phase 3 INShore trial. The treatment offers a steroid-sparing option but has higher serious adverse event rates requiring careful monitoring.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 25 Sep 2026 and 30 Sep 2026.